Table 2.
Characteristic | Category | Number | Percent |
---|---|---|---|
Pre-diagnostic prostate specific antigen (PSA) level (ng/ml) | |||
<4 | 6 | 7 | |
4 to <20 | 36 | 44 | |
20 to <50 | 22 | 27 | |
50 to <100 | 7 | 9 | |
100+ | 10 | 13 | |
Total | 81 | 100 | |
Gleason grade | |||
5 (low) | 1 | 2 | |
6 | 32 | 42 | |
7 | 24 | 32 | |
8 | 12 | 16 | |
9 | 5 | 6 | |
10 (high) | 2 | 2 | |
Total | 76 | 100 | |
Clinical stagea | |||
T1 | 29 | 36 | |
T2 | 26 | 32 | |
T3 | 11 | 14 | |
T4 | 15 | 18 | |
Total | 81 | 100 | |
Aggressive diseaseb | |||
Yes | 60 | 74 | |
No | 21 | 26 | |
Total | 81 | 100 |
T1 tumor present but not palpable or detectable with imaging, T2 tumor can be palpated on examination but has not spread beyond the prostate capsule, T3 tumor has spread through the prostate capsule, T4 tumor has metastasized
Aggressive disease defined as Gleason grade 7–10, Stage T3–T4, or PSA >20ng/ml